Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

ward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to raise additional funds or enter strategic alliances, advance development of our potential products and complete research and development, including pre-clinical and clinical studies, the continuation of arrangements with partners and customers, competition, government regulation and approvals, and general economic conditions. For example, we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue, or we may not be able to raise capital or generate revenue to finance our operations. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

                                SCOLR Pharma, Inc.

                             CONDENSED BALANCE SHEETS

                                              June 30, 2009   December 31,
                                               (Unaudited)        2008
                                              -------------   --
'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... that provides innovative genetic analysis solutions, and Mayo ... laboratory services in the United States ... testing patents and applications. "We have great ... patient care, and we welcome the opportunity to partner ...
(Date:7/29/2014)... , July 29, 2014  The Society for ... and updated program for the 9 th ... 2014 in Amelia Island , Florida.  The ... investigators remains unchanged, however, the topics and format ... networking opportunity among all stakeholders with a continued ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... Rockville, MD (PRWEB) July 29, 2014 ... (ITI), a vaccine pioneer in the biotechnology industry, ... firm Newport Coast Securities, Inc. to explore financing ... commercializing LAMP-vax technology, a breakthrough vaccine platform with ... immunotherapy market. The company exclusively licensed the well-established ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... , ... • chemiluminescence , , ... enzymes exist, their activities having wide-ranging regulatory responses. Many kinases ... as inflammation and cancer, so identifying modulators of kinase and ...
... , , , ... Hancock, Elaine Adie, Molly Price-Jones, Stephen Game & Stuart Swinburne , ... Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA England, ... , As high throughput imaging systems, analysis ...
... , ... The Maynard Centre, Cardiff, UK , ... and the development of high-throughput image analysis platforms such as the IN ... we describe the application of two stable cell lines expressing green fluorescent ...
Cached Biology Technology:Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 2Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 3Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 2siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 3siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 5siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 6siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 7
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... Aarhus University researchers have developed an easier method ... strengthen the work involved in diagnosing diseases. , ... provides a strong partnership that can be used ... conjugates which tag proteins with DNA ... sensitive detection and visualisation of biological material. The ...
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
Breaking Biology News(10 mins):Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... The University of Houston department of health and human ... Life (SL) thanks to grants from the UH Faculty ... of the University of Southern California-Annenberg School for Communication. ... ground in Second Life for the benefit of our ...
... The life expectancy for patients with human immunodeficiency ... since the late 1990s thanks to advancements in antiretroviral ... at Birmingham (UAB) and Simon Fraser University in Vancouver, ... nearly 40 percent drop in AIDS deaths among 43,355 ...
... on the brain" must have shunts implanted to drain the ... While shunts do their job well, the rate of ... of reasons, which requires putting the child through another surgery ... potential additional neurological complications and an increased risk of death. ...
Cached Biology News:Second Life a first for UH department of health and human performance 2Anti-HIV therapy boosts life expectancy more than 13 years 2Antimicrobial sutures reduce infections in brain shunt surgery, study finds 2
... includes 1. Scanning of gel(s) 2. ... tryptic in-gel digestion and peptide extraction ... 5. Acquisition of PMF (Peptide Mass ... TOF/TOF) 6. Acquisition of PFF (Peptide ...
... Nucleic acid hybridization Preparation ... mg BSA, 50 mg ficoll ... with 5 ml of water ... for molecular biology Density: 1.00 ...
... ImageXpress 5000A automated cellular imaging and analysis ... system designed specifically for rapid acquisition and ... cell-based screening. ImageXpress is fast. Scanning ... (1280 x 1024 pixels), with two fluorescence ...
... Antibody Capture Kit eliminates ... optimization steps typically required ... This kit enables the ... multiple antigens based on ...
Biology Products: